

Personal Data

Prof. Dr. med. Stephan Thureau, FEBO
Department of Ophthalmology, LMU University Hospital, LMU Munich

Medical School:	Universities of Kiel and Munich, 3 rd Staatsexamen 1986
Approbation:	June 10, 1986, Bayerisches Staatministerium des Inneren
Doctoral Thesis:	1988 with Prof. Gert Riethmüller in the Institute for Immunology LMU Munich. Topic: Expression of HLA-B27 on murine cells and generation of antibodies against HLA-B27
Ophthalmology Training:	1987: Prof. Lund and later Prof. Kampik at the Dept. of Ophthalmology, Ludwig-Maximilians-University, Munich
Postdoctoral Fellowship:	1989 - 1990 with Dr. Nussenblatt and Dr. Caspi at the Lab. of Immunoregulation, National Eye Inst. of the NIH, Bethesda, USA Training in clinical uveitis Research projects: - Oral tolerance induction in experimental autoimmune uveitis - Interleukins in experimental autoimmune uveitis - Chimeric immunotoxins in experimental keratoplasty - Preparations for trial of oral tolerance in uveitis patients at the National Eye Institute
Lab of Immunobiology:	1991: Establishing the Lab of Immunobiology within the Department of Ophthalmology together with Dr. Gerhild Wildner with the financial support of the German Research Society (DFG)
German Board Exam Ophthalmology:	1994 "Specialist in Ophthalmology"
Fellow of the European Board of Ophthalmology	2003 "FEBO"
Habilitation:	2000 on "New immunologic treatments in uveitis"
Associate Professor	June 2008
Clinical focus:	Uveitis and inflammation ("uveitis center" since 1994), Medical retina
Scientific focus:	- Studies on regulatory cells in uveitis and oral tolerance - Role of HLA in uveitis - Migratory patterns of inflammatory cells in uveitis - Intravital fluorescence microscopy Development of controlled clinical trials in Europe and USA for a peptide to treat uveitis using the mechanism of oral tolerance (holder of national and international patents)
Student teaching	Since 1990 student teaching and organization (ophthalmology) 2002 – 2004: Organization of the new modul "Nerve system and sensorium" with Ophthalmology, Otorhinolaryngology, Dermatology, Neurology, Psychiatry and Pharmacology at the Medical School of the Ludwig-Maximilians-University in Munich Lectures, seminars, bedside-teaching in Ophthalmology Seminars and bedside-teaching in Rheumatology
Reviewer activities	Reviewer for multiple national and international ophthalmological journals

Visiting professorship	2013: Dept. of Ophthalmology, University of New South Wales, Sydney, Australia 2014: Advanced Eye Center, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Memberships	Association for Research in Vision and Ophthalmology (ARVO) German Society for Immunology (DGfI), German Ophthalmological Society (DOG), European Association for Vision and Eye Research (EVER), International Ocular Inflammation Society (IOIS), Society for Ophthalmo-Immunoinfectiology in Europe (SOIE)
Certificates	2012, 2014, 2016, 2019, 2021 GCP accreditations.
Clinical studies	Phase 1 trial " A safety and efficacy study of intravitreal PP-001 in patients with chronic, non-infectious uveitis having chronic inflammation (NCT03634475) Phase I: Treatment of uveitis by induction of immunologic tolerance Phase III: Intraocular steroids in uveitis [BLP 415-002: A Multicenter, Randomized, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide (0.5mg) Implant Compared to Standardized Therapy in Patients with Non Infectious Uveitis Affecting the Posterior Segment of the Eye] Phase III: Intraocular immunosuppressive treatment fo uveitis: A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye EudraCT Number 2011-001595-19; DE-109 Phase III: Systemic TNF-blockade of uveitis [M10-877: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate-, Posterior-, or Pan-uveitis – VISUAL I], EudraCT Number 2009-016095-68 [M10-880: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis - VISUAL II], EudraCT Number 2009-016008-22 [M11-327: A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis - VISUAL III] EudraCT Number 2009-016196-29 Phase III: Specific side effects of systemic treatment of multiple sclerosis (2 different studies) Phase II: Treatment of Optic neuritis [EudraCT Number: 2013-002515-10: Treatment of Optic Neuritis with Erythropoietin (TONE)] EudraCT Number: 2013-002515-10 Phase I: A safety study of intravitreal PP-001 in patients with chronic, non-infectious uveitis having chronic inflammation. EudraCT Number 2016-000412-15